BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines amgen In-Licensed Products — Total Net Product Revenue ($M) ($M)
Form 10-Q / 10-K MD&A & Segment Disaggregation Note (XBRL)
Latest, FY2025
486
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 8-K (filed 2026-02-26)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Amgen In-Licensed Products — Total Net Product Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 486 | – | Form 8-K (filed 2026-02-26) ↗ |
Breakdown
What makes up amgen in-licensed products — total net product revenue ($m)
Cite this data
StockData. (2026). BeOne Medicines Amgen In-Licensed Products — Total Net Product Revenue ($M) ($M), annual FY2025–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_amgen_tot
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.